BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 28196634)

  • 1. Objective, domain-specific HER2 measurement in uterine and ovarian serous carcinomas and its clinical significance.
    Carvajal-Hausdorf DE; Schalper KA; Bai Y; Black J; Santin AD; Rimm DL
    Gynecol Oncol; 2017 Apr; 145(1):154-158. PubMed ID: 28196634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.
    Carvajal-Hausdorf DE; Schalper KA; Pusztai L; Psyrri A; Kalogeras KT; Kotoula V; Fountzilas G; Rimm DL
    J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25991002
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-DM1, a novel antibody-drug conjugate, is highly effective against primary HER2 overexpressing uterine serous carcinoma in vitro and in vivo.
    English DP; Bellone S; Schwab CL; Bortolomai I; Bonazzoli E; Cocco E; Buza N; Hui P; Lopez S; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Cancer Med; 2014 Oct; 3(5):1256-65. PubMed ID: 24890382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Her2/neu extracellular domain shedding in uterine serous carcinoma: implications for immunotherapy with trastuzumab.
    Todeschini P; Cocco E; Bellone S; Varughese J; Lin K; Carrara L; Guzzo F; Buza N; Hui P; Silasi DA; Ratner E; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Br J Cancer; 2011 Oct; 105(8):1176-82. PubMed ID: 21915118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting HER2 in ovarian and uterine cancers: challenges and future directions.
    Teplinsky E; Muggia F
    Gynecol Oncol; 2014 Nov; 135(2):364-70. PubMed ID: 25220628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patients.
    Vassilakopoulou M; Togun T; Dafni U; Cheng H; Bordeaux J; Neumeister VM; Bobos M; Pentheroudakis G; Skarlos DV; Pectasides D; Kotoula V; Fountzilas G; Rimm DL; Psyrri A
    PLoS One; 2014; 9(6):e99131. PubMed ID: 24968015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo.
    Tymon-Rosario J; Bonazzoli E; Bellone S; Manzano A; Pelligra S; Guglielmi A; Gnutti B; Nagarkatti N; Zeybek B; Manara P; Zammataro L; Harold J; Mauricio D; Buza N; Hui P; Altwerger G; Menderes G; Ratner E; Clark M; Andikyan V; Huang GS; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2021 Nov; 163(2):334-341. PubMed ID: 34452746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.
    Groeneweg JW; Hernandez SF; Byron VF; DiGloria CM; Lopez H; Scialabba V; Kim M; Zhang L; Borger DR; Tambouret R; Foster R; Rueda BR; Growdon WB
    Clin Cancer Res; 2014 Dec; 20(24):6517-6528. PubMed ID: 25294905
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2.
    Nicoletti R; Lopez S; Bellone S; Cocco E; Schwab CL; Black JD; Centritto F; Zhu L; Bonazzoli E; Buza N; Hui P; Mezzanzanica D; Canevari S; Schwartz PE; Rutherford TJ; Santin AD
    Clin Exp Metastasis; 2015 Jan; 32(1):29-38. PubMed ID: 25398397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor suppressor gene, cell surface adhesion molecule, and multidrug resistance in Müllerian serous carcinomas: clinical divergence without immunophenotypic differences.
    Soslow RA; Slomovitz BM; Saqi A; Baergen RN; Caputo TA
    Gynecol Oncol; 2000 Dec; 79(3):430-7. PubMed ID: 11104615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma.
    Mutlu L; Manavella DD; Bellone S; McNamara B; Harold JA; Mauricio D; Siegel ER; Buza N; Hui P; Hartwich TMP; Yang-Hartwich Y; Demirkiran C; Verzosa MSZ; Altwerger G; Ratner ES; Huang GS; Clark M; Andikyan V; Azodi M; Dottino PR; Schwartz PE; Santin AD
    Mol Cancer Ther; 2023 Dec; 22(12):1404-1412. PubMed ID: 37676984
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
    Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
    J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.
    Schwab CL; Bellone S; English DP; Roque DM; Lopez S; Cocco E; Nicoletti R; Bortolomai I; Bonazzoli E; Ratner E; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Santin AD
    Br J Cancer; 2014 Oct; 111(9):1750-6. PubMed ID: 25268372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PIK3CA oncogenic mutations represent a major mechanism of resistance to trastuzumab in HER2/neu overexpressing uterine serous carcinomas.
    Black JD; Lopez S; Cocco E; Bellone S; Altwerger G; Schwab CL; English DP; Bonazzoli E; Predolini F; Ferrari F; Ratner E; Silasi DA; Azodi M; Schwartz PE; Santin AD
    Br J Cancer; 2015 Sep; 113(7):1020-6. PubMed ID: 26325104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine Serous Carcinoma with HER2/Neu Expression.
    Black J; Menderes G; Bellone S; Schwab CL; Bonazzoli E; Ferrari F; Predolini F; De Haydu C; Cocco E; Buza N; Hui P; Wong S; Lopez S; Ratner E; Silasi DA; Azodi M; Litkouhi B; Schwartz PE; Goedings P; Beusker PH; van der Lee MM; Timmers CM; Dokter WH; Santin AD
    Mol Cancer Ther; 2016 Aug; 15(8):1900-9. PubMed ID: 27256376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma.
    Al-Hussaini M; Stockman A; Foster H; McCluggage WG
    Histopathology; 2004 Feb; 44(2):109-15. PubMed ID: 14764054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1.
    Nonagase Y; Yonesaka K; Kawakami H; Watanabe S; Haratani K; Takahama T; Takegawa N; Ueda H; Tanizaki J; Hayashi H; Yoshida T; Takeda M; Chiba Y; Tamura T; Nakagawa K; Tsurutani J
    Oncotarget; 2016 Dec; 7(51):84860-84871. PubMed ID: 27768588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group.
    Bookman MA; Darcy KM; Clarke-Pearson D; Boothby RA; Horowitz IR
    J Clin Oncol; 2003 Jan; 21(2):283-90. PubMed ID: 12525520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [T-DM1 and pertuzumab: emerging anti-HER2 therapeutics].
    Noguchi E; Shimizu C
    Gan To Kagaku Ryoho; 2013 Jan; 40(1):10-4. PubMed ID: 23306913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.
    Krop I; Winer EP
    Clin Cancer Res; 2014 Jan; 20(1):15-20. PubMed ID: 24135146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.